AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35911702
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy (iC)
Trial: 35911824
Drug: Stoss therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stoss therapy
Trial: 35913656
Drug: Mean daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mean daily PLGS duration between 157.5 and 174.4 min/day
Trial: 35913656
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin percentage < 52.0%
Trial: 35913656
Drug: Total Daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Daily Dose (TDD) adaptation
Trial: 35914096
Drug: Vision therapy/exercises
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vision therapy/exercises (n = 35)
Trial: 35914227
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplant with gene therapy (ASCT-GT)
Trial: 35914239
Drug: Doxorubicin/cyclophosphamide (A/C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin/cyclophosphamide (A/C) followed by paclitaxel for neoadjuvant systemic therapy (NAST)
Trial: 35914538
Drug: ReStoreD: Promoting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ReStoreD: Promoting Resilience after Stroke in Dyads (8-week self-administered dyadic positive psychology intervention)
Trial: 35914905
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green clearance test (IGT) administered to the donor, with a cut-off value of 13% for plasma disappearance rate (PDR).
Trial: 35915019
Drug: PCSK9 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 levels measured at baseline and after 5 days (ng/ml)
Trial: 35915020
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy
Trial: 35915157
Drug: Panitumumab (anti-EGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (anti-EGFR monoclonal antibody)
Trial: 35915157
Drug: Standard third-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard third-line treatments
Trial: 35915419
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET) initiation by 12-month interview
Trial: 35915419
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy (ET) continuation for ≥12 months by 24-month interview
Trial: 35915738
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with fluticasone furoate/vilanterol (FF/VI)
Trial: 35915738
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with umeclidinium/vilanterol (UMEC/VI)
Trial: 35916675
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DS and LS measurements from 2D shear-wave elastography (SWE)
Trial: 35916707
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of iQuit Mindfully text messages and mindfulness videoconference groups
Trial: 35918666
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period with no reduction in cost for the contraceptive implant, reduced price for hormonal IUD, sliding scale for copper IUD (September 2015-March 2016)
Trial: 35918703
Drug: Multi-level hypertension
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-level hypertension control program including a hypertension patient registry, performance and quality reporting, simplified treatment guidelines, access to essential medicines, team-based care, health coaching, and home blood pressure monitoring.
Trial: 35918703
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase of sequential registration and empanelment of hypertensive patients at participating primary healthcare centers.
Trial: 35918743
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) injections, mean number of injections by Month 12: 3.7 ± 1.8 (treatment-naïve), 4.0 ± 2.2 (previously treated).
Trial: 35918757
Drug: Vestibular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular therapy (VT) for 8 weeks, ~25-min office sessions with a vestibular therapist
Trial: 35918757
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control therapy for 8 weeks
Trial: 35919065
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose computed tomography (ULD-CT)
Trial: 35919538
Drug: Urinary CCL14
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary CCL14 cutoff of 1.3 ng/ml
Trial: 35919538
Drug: Urinary CCL14
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary CCL14 cutoff of 13 ng/ml
Trial: 35919538
Drug: CCL14 concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCL14 concentration between 1.3 and 13 ng/ml
Trial: 35919766
Drug: Tight Control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight Control (TC) management with TNFi dose changes informed by biochemical markers of inflammation
Trial: 35920743
Drug: elbasvir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elbasvir (50 mg)/grazoprevir (100 mg)
Trial: 35920783
Drug: NC-6300 (Nanoparticle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NC-6300 (Nanoparticle Epirubicin) at a dose of 150 mg/m2 intravenously (IV) once every 3 weeks
Trial: 35921139
Drug: Secure Messaging
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Secure Messaging for Medication Reconciliation Tool (SMMRT)
Trial: 35921449
Drug: L9LS administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L9LS administered intravenously or subcutaneously at doses of 1 mg, 5 mg, or 20 mg per kilogram of body weight
Trial: 35922819
Drug: SMC drugs
RxNorm normalized name: prosolv SMCC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC drugs only
Trial: 35922819
Drug: SMC drugs
RxNorm normalized name: prosolv SMCC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC drugs and praziquantel
Trial: 35922819
Drug: SMC drugs
RxNorm normalized name: prosolv SMCC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMC drugs and albendazole and praziquantel
Trial: 35922861
Drug: Eltanexor 10
RxNorm normalized name: Eltanexor
DrugBank: Eltanexor (DB16153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanexor 10 mg, administered on days 1-5 each week of a 28-day cycle
Trial: 35922861
Drug: Eltanexor 20
RxNorm normalized name: Eltanexor
DrugBank: Eltanexor (DB16153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanexor 20 mg, administered on days 1-5 each week of a 28-day cycle
Trial: 35922861
Drug: Eltanexor (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltanexor (both doses combined)
Trial: 35922860
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid therapy duration
Trial: 35922868
Drug: Cultivated oral
RxNorm normalized name: Cultivated mushroom
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultivated oral mucosal epithelial sheet transplantation
Trial: 35923658
Drug: Aripiprazole tablets
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole tablets with sensor (AS) - high engagement group
Trial: 35923658
Drug: Aripiprazole tablets
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole tablets with sensor (AS) - moderate engagement group
Trial: 35923658
Drug: Aripiprazole tablets
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole tablets with sensor (AS) - discontinued group
Trial: 35925040
Drug: Person-centred, theory-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Person-centred, theory-based oral health education program
Trial: 35925555
Drug: Fexinidazole 1200
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexinidazole 1200 mg/day for 2 weeks
Trial: 35925555
Drug: Fexinidazole 1800
RxNorm normalized name: fexinidazole
DrugBank: Fexinidazole (DB12265)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexinidazole 1800 mg/day for 2 weeks
Trial: 35925686
Drug: Anticoagulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation treatment for acute VTE
Trial: 35927231
Drug: Human umbilical
RxNorm normalized name: Human umbilical tissue derived cells
DrugBank: Human umbilical tissue derived cells (DB17907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human umbilical cord-derived mesenchymal stem cells (UMSCs) infusion
Trial: 35927710
Drug: Intralesional T-VEC
RxNorm normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intralesional T-VEC (up to 4 mL, first dose as seroconversion dose) and systemic nivolumab (240 mg flat dose) every 2 weeks for four courses of T-VEC and three doses of nivolumab
Trial: 35927713
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment and use of insecticide-treated nets
Trial: 35928870
Drug: UCPVax (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UCPVax (therapeutic cancer vaccine composed of two peptides derived from telomerase) combined with atezolizumab (anti-PD-L1)
Trial: 35929455
Drug: Insulin receptor
RxNorm normalized name: Insulin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin receptor substrate-1 rs956115 genotype
Trial: 35929986
Drug: AZD5305 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5305 at doses ≥0.1 mg/kg once daily
Trial: 35929986
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg/kg once daily
Trial: 35930336
Drug: Weekly assessments
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly assessments during the mobile sensing phase for 9 months.
Trial: 35931600
Drug: Immediate medical
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate medical treatment (IMT) started less than 3 months after metastatic diagnosis
Trial: 35931600
Drug: Delayed medical
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed medical treatment (DMT)
Trial: 35931600
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment of metastasis (LTM)
Trial: 35931943
Drug: Tucatinib 300
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tucatinib 300 mg dose
Trial: 35932306
Drug: BMC injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMC injections with higher CFU-F concentrations
Trial: 35932387
Drug: Envafolimab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab 1.0 mg/kg, 2.5 mg/kg, and 5.0 mg/kg SC QW (10 patients)
Trial: 35932387
Drug: Envafolimab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab 2.5 mg/kg and 5.0 mg/kg SC Q2W (16 patients)
Trial: 35932387
Drug: Envafolimab 300
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Envafolimab 300 mg SC Q4W (9 patients)
Trial: 35932388
Drug: Pevonedistat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pevonedistat (50 mg/m)
Trial: 35932628
Drug: Nilotinib treatment
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib treatment
Trial: 35932876
Drug: Asymptomatic short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asymptomatic short cervix treatment (200 mg vaginal progesterone, cerclage, or pessary)
Trial: 35933358
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) treatment 2 g/kg monthly for three months
Trial: 35933915
Drug: Cobicistat co-administration
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cobicistat co-administration with osimertinib
Trial: 35934010
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg IV) plus tremelimumab (75 mg IV) for four cycles, followed by durvalumab alone every 4 weeks for up to 12 months.
Trial: 35934287
Drug: Cilofexor 100
RxNorm normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilofexor 100 mg daily
Trial: 35935379
Drug: Collection of
RxNorm normalized name: Reveos Select CPD with AS-5 Red Cell Preservative Solution For Collection Of 500ml Of Blood KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collection of PFAPA patient's demographics, medical histories, symptoms, triggers/risk factors, therapies, and impact on healthcare systems
Trial: 35935445
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine (0.75 mg/kg)
Trial: 35935445
Drug: Escitalopram (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (15 mg) and aripiprazole (5 mg)
Trial: 35935634
Drug: SGLT2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitors (SGLT2i) administered to Group I with inadequately controlled T2D (mean fasting plasma glucose (FPG) of ≥7 mmol/L)
Trial: 35935634
Drug: Adequately controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequately controlled T2D (mean FPG of <7 mmol/L)
Trial: 35935634
Drug: No diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No diabetes (mean FPG of ≤ 5.5 mmol/L)
Trial: 35935863
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (2 g/day)
Trial: 35935974
Drug: BNT162b2 Pfizer-BioNTech
RxNorm normalized name: Pfizer-BioNTech COVID-19 Vaccine
DrugBank: Tozinameran (DB15696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 Pfizer-BioNTech vaccine
Trial: 35938545
Drug: Bipolar Androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bipolar Androgen Therapy (BAT) followed by abiraterone or enzalutamide
Trial: 35939367
Drug: Antiseizure medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseizure medications (ASMs)
Trial: 35939367
Drug: Drug-drug interactions
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-drug interactions between ASMs
Trial: 35939663
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy and exercise 3 times a week for 4 weeks
Trial: 35939919
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy program (MTP) applied to craniomandibular structures, four weekly sessions
Trial: 35939919
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy program (MTP)
Trial: 35940054
Drug: Sequential application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A)
Trial: 35940054
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination of fluoropyrimidine, irinotecan, and bevacizumab (Arm B)
Trial: 35940054
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in patients older than 70 years
Trial: 35940054
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment in patients with RAS mutant tumours
Trial: 35940054
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment in RAS/BRAF wild-type tumours
Trial: 35940055
Drug: TQ-B3139 (50-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3139 (50-800 mg) administered continuously in 28-day cycles, with expansion stage starting at 200 mg BID.
Trial: 35940055
Drug: TQ-B3139 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-B3139 at dose level ≥200 mg BID.
Trial: 35940825
Drug: Varlilumab (0.1-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab (0.1-10 mg/kg) with nivolumab (3 mg/kg) administered once every 2 weeks (Phase 1)
Trial: 35940825
Drug: Varlilumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab (3 mg/kg once every 2 weeks, 3 mg/kg once every 12 weeks, and 0.3 mg/kg once every 4 weeks) with nivolumab (240 mg once every 2 weeks) (Phase 2)
Trial: 35940825
Drug: Varlilumab and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varlilumab and nivolumab combination
Trial: 35940836
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol (up to 20 mg) and glyceryl trinitrate (GTN) (0.8 mg and 0.4 mg)
Trial: 35940836
Drug: Reduced GTN
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced GTN doses
Trial: 35940836
Drug: GTN dose
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN dose reduction
Trial: 35941015
Drug: Postoperative pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative pain treatment
Trial: 35941028
Drug: Trastuzumab (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (loading dose 8 mg/kg, then 6 mg/kg every 3 weeks) and oral pyrotinib (400 mg per day until progression)
Trial: 35941212
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose blinatumomab (maximum 112 mcg/d after initial weekly dose escalation) for 8 weeks induction and 4 weeks consolidation.
Trial: 35941372
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab deruxtecan (5.4 mg/kg bodyweight intravenously once every 3 weeks)
Trial: 35941609
Drug: Formulation 3
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation 3 (MMT peel powder)
Trial: 35941653
Drug: Conventional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional care supported by eHealth (tablet)
Trial: 35941653
Drug: eHealth (tablet)
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eHealth (tablet)
Trial: 35942508
Drug: Soluble urokinase-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble urokinase-type plasminogen activator receptor (suPAR) in Stage C/D
Trial: 35942675
Drug: Beta-blocker intake
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker intake
Trial: 35943168
Drug: Precision cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision cancer medicine (PCM)
Trial: 35943899
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (BI) plus oral hypoglycemic drugs (OADs)
Trial: 35943899
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin plus oral hypoglycemic drugs (OADs)
Trial: 35944767
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) treatment
Trial: 35945244
Drug: nab-paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel with carboplatin followed by concomitant FHX (infusional 5-fluorouracil, hydroxyurea and twice-daily radiation therapy) plus nab-paclitaxel at a dose of 100 mg/m